Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 12, 2014, Pages 1741-1750

  Merker, Andrew ^a   Danziger, Larry H ^a   Rodvold, Keith A ^a   Glowacki, Robert C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Acute bacterial skin and skin structure infections; Antibiotic resistance; Ceftaroline; Community acquired bacterial pneumonia; Methicillin resistant Staphylococcus aureus

Indexed keywords

AZTREONAM; CEFTAROLINE FOSAMIL; CEFTRIAXONE; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PPI-0903;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ADVERSE OUTCOME; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; BLOOD TOXICITY; COMMUNITY ACQUIRED BACTERIAL PNEUMONIA; DIARRHEA; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; LOEFFLER PNEUMONIA; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; RISK ASSESSMENT; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; HUMANS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84911455792     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.972932     Document Type: Review

References (56)

1. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multi-drug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343(26):1917-24
2. Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes, and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010;16:402-10
3. Klevens RM, Edwards JR, Tenover FC, et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in US hospitals, 1992-2003. Clin Infect Dis 2006;42:389-91
4. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-46
5. Ceftaroline fosamil [package insert]. Forrest Pharmaceuticals; St. Louis, MO: 2010
6. Nagai K, Davies TA, Jacobs MR, Appelbaum PC. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate and -Resistant pneumococci. Antimicrob Agents Chemother. 2002;46(5):1273-80
7. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillinbinding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2010;54(5):1670-7
8. Sader HS, Fritsche TR, Kaniga K, et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005;49(8):3501-12
9. Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52(9):3398-407
10. Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009;55(3):1271-4
11. Jones RN, Farrell DJ, Mendes RE, Sader HS. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother 2011;66(3):69-80
12. Pfaller MA, Farrell DJ, Sader HS, Jones RN. AWARE ceftaroline surveillance program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States. Clin Infect Dis 2012;55(3):S187-93
13. Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52(3):1153-5
14. Pfaller MA, Flamm RK, Sader HS, Jones RN. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). Diagn Microbiol Infect Dis 2014;78:422-8
15. Mushtaq S, Warner M, Ge Y, et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007;60:300-11
16. Fenoll A, Aguilar L, Robledo O, et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin and cefotaxime. Antimicrob Agents Chemother 2008;52(11):4209-10
17. McGee L, Biek D, Ge Y, et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009;53(2):552-6
18. Steed ME, Vidaillac C, Winterfield P, et al. Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2012;56(5):2691-5
19. Flamm RK, Sader HS, Farrell DJ, Jones RN. Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers. Antimicrob Agents Chemother 2014;58(4):2468-71
20. Saravolatz L, Pawlak J, Johnson L. In vitro activity of ceftaroline against community-associated methicillinresistant, vancomycin-intermediate, vancomycin-resistant and daptomycinnonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010;54(7):3027-30
21. Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin or vancomycin from U.S. Hospitals, 2008 to 2011. Antimicrob Agents Chemother 2013;57(7):3178-81
22. Sader HS, Flamm RK, Farrell DJ, Jones RN. Activity analyses of staphylococcal isolates from pediatric, adult and elderly patients: AWARE ceftaroline surveillance program. Clin Infect Dis 2012;55(3):S181-6
23. Jones RN, Fritsche TR, Ge Y, et al. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005;56:1047-52
24. Mendes RE, Tsakris A, Sader HS, et al. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 2012;67:1321-4
25. Murray B, Shinabarger D, Biek D, et al. Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline (CPT) [abstract C1-185]. 46th Annual Meeting Infectious Diseases Society of America; Washington, DC; 2008
26. Mushtaq S, Livermore DM. AmpC induction by ceftaroline. J Antimicrob Chemother 2010;65(3):586-8
27. Ge Y, Redman R, Floren L, et al. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions [abstract A-1937]. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA; 2006
28. Ge Y, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903) [abstract A-1935]. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA; 2006
29. Riccobene T, Puskin R, Jandourek A. Penetration of ceftaroline into epithelial lining fluid in healthy adult subjects [abstract A-469]. 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Denver, CO; 2013
30. Riccobene TA, Su SF, Rank D. Singleand multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Antimicrob Agents Chemother 2013;57(3):1496-504
31. Ge Y, Floren L, Redman R, et al. Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects [abstract A-1936]. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA; 2006
32. Riccobene T, Jakate A, Rank D. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects and subjects with renal impairment or endstage renal disease requiring hemodialysis. J Clin Pharmacol 2014;54(7):742-52
33. Ge Y, Thye D, Liao S, Talbot G. Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI) [abstract A-1939]. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA; 2006
34. Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokineticpharmacodynamic target. Antimicrob Agents Chemother 2006;50(4):1376-83
35. MacGowan AP, Noel AR, Tomaselli S, Bowker KE. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 2013;57(6):2451-6
36. Keel RA, Crandon JL, Nicolau DP. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011;55(9):4028-32
37. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycinintermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009;53(11):4712-17
38. Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. Antimicrob Agents Chemother 2014;58(2):672-7
39. Croisier-Bertin D, Piroth L, Charles PE, et al. Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing. Antimicrob Agents Chemother 2011;55(7):3557-63
40. Bhalodi AA, Crandon JL, Biek D, Nicolau DP. Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model. Antimicrob Agents Chemother 2012;56(12):6160-5
41. Jacqueline C, Amador G, Caillon J, et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 2010;75:1749-52
42. Stucki A, Acosta F, Cottagnoud M, Cottagnoud P. Efficacy of ceftaroline fosamil against Escherichia coli and Klebsiella pneumoniae strains in a rabbit meningitis model. Antimicrob Agents Chemother 2013;57(12):5808-10
43. Van Wart SA, Ambrose PG, Rubino CM, et al. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2014;58(2):885-91
44. Van War SA, Forest A, Khariton T, et al. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. J Clin Pharmacol 2013;53(11):1155-67
45. Ge Y, Liao S, Thye D, Talbot GH. Ceftaroline (CPT) dose adjustment recommendations for subjects with mild or moderate renal impairment (RI) [abstract A-35]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL; 2007
46. Bhavnani SM, Hammel JP, Van Wart SA, et al. Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother 2013;57(12):6348-50
47. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010;51(6):641-50
48. Ho TT, Cadena J, Childs LM, et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 2012;67:1267-70
49. Lin JC, Aung G, Thomas A, et al. The use of ceftaroline fosamil in methicillinresistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 2013;19:42-9
50. Casapao AM, Davis SL, Barr VO, et al. A large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 2014;58(5):2541-6
51. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51(10):3612-16
52. Griffiths CL, Gutierrez KC, Pitt RD, Lovell RD. Eosinophilic pneumonia induced by ceftaroline. Am J Health Syst Pharm 2014;71:403-6
53. Desai KR, Burdette SD, Polenakovik HM, et al. Ceftaroline-induced eosinophilic pneumonia. Pharmacotherapy 2013;33(7):e166-9
54. McConeghy KW, Danziger LH, Rodvold KA. A signal of leukopenia with ceftaroline in the FDA adverse event reporting system [abstract A-471]. 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Denver, CO; 2013
55. Rimawi RH, Frenkel A, Cook PP. Ceftaroline-a cause for neutropenia. J Clin Pharm Ther 2013;38(4):330-2
56. Jain R, Chan J, Rogers L, et al. High incidence of discontinuation due to adverse events in patients treated with ceftaroline. Pharmacotherapy 2014;34:758-63